Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2013

View Archived Issues

Merck Serono funds new nonprofit EspeRare Foundation

Rare variant of CALCRL gene associated with diabetic nephropathy susceptibility

Intec Pharma receives Michael J. Fox Foundation grant

Japanese scientists disclose new vaccines for tuberculosis

NT-113, a pan-erbB inhibitor active against brain metastases in rodents

First-in-human results for ARQ-092 demonstrate disease stabilization in patients with solid tumors

Potential repurposing of old anti-inflammatory drug for tuberculosis

Bristol-Myers Squibb presents the discovery of novel HCV entry pathway inhibitors

Durect submits NDA for Posidur pain relief depot

Roche synthesizes new series of PDE10A inhibitors

Merck & Co. patents novel JAK1/JAK2 inhibitors

Rhythm begins phase II trial of RM-131 for lower GI function disorders

Bayer Intellectual Property discloses new anticancer agents

Aerocrine's Niox Mino device approved in Canada

Santhera to continue phase III Catena trial in DMD

FDA to consider accelerated approval for Sarepta Therapeutics' eteplirsen

Isis Innovation divulges new CB2 receptor agonists

Meiji Seika Pharma acquires Japanese rights to asenapine

New agents inhibiting CYP11B2 disclosed by Merck & Co.

Eli Lilly reports data from phase III trials of dulaglutide in type 2 diabetes

Authorities expand European approval of Berinert in HAE

First patient enrolled in global phase III program for Amikacin Inhale

Zymeworks achieves second milestone in collaboration with Merck & Co.

AnGes and Shionogi agree to begin phase I testing of NF-kappaB decoy oligodeoxynucleotide

Topline results reported from phase II study of GMI-1070